Transatlantic Collaboration in Nuclear Energy

Search documents
NANO Nuclear Signs Letter of Intent with Cambridge Atom Works to Sell its Portable ODIN™ Reactor Technology
Globenewswire· 2025-09-17 12:05
Core Viewpoint - NANO Nuclear Energy Inc. has signed a letter of intent to sell its ODIN™ low-pressure coolant microreactor design to Cambridge Atom Works for a total of $6.2 million, allowing the company to focus on its gas-cooled reactor portfolio and enhance developmental efficiencies [2][3][4]. Group 1: Transaction Details - The sale includes a $250,000 upfront non-refundable down payment and a $5.95 million payment scheduled for 2026, along with future low single-digit royalties based on net sales if ODIN is commercialized [3]. - The transaction is subject to the execution of definitive documentation and customary closing conditions [3]. Group 2: Strategic Implications - The sale of ODIN is part of NANO Nuclear's strategy to streamline its product line and concentrate resources on its gas-cooled microreactors: KRONOS MMR, LOKI MMR, and ZEUS [4][6]. - This strategic move aligns with the recent Atlantic Partnership for Advanced Nuclear Energy between the U.S. and the U.K., which aims to accelerate nuclear power development and streamline regulatory frameworks [5][6]. Group 3: Product Portfolio and Development - NANO Nuclear's flagship KRONOS MMR is designed to deliver up to 45 MWth in a single-unit configuration and can scale to gigawatt-level power in multi-unit configurations, enhancing energy resiliency and economics [6]. - The company is actively working with the U.S. Nuclear Regulatory Commission to license the KRONOS MMR and has initiated site preparation activities at the University of Illinois Urbana-Champaign [6][7]. Group 4: Future Outlook - The retention of LOKI MMR and ZEUS microreactors is seen as a strategic decision due to their shared features with the KRONOS MMR, which is expected to provide synergistic benefits across the portfolio [9][10]. - The company anticipates that the development of KRONOS MMR will directly benefit LOKI and ZEUS, enhancing performance and regulatory efficiency [10].